La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CERo Therapeutics Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CERo Therapeutics Hldgs..

CERo Therapeutics Hldgs (NASDAQ:CEROW) Azioni, Catena delle Opzioni

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.41 by 8.82 percent. This is a 25.37 percent decrease over earnings of $2.05 per share from the same period last year. The company reported quarterly sales of $895.312 million which missed the analyst consensus estimate of $900.987 million by 0.63 percent. This is a 5.69 percent increase over sales of $847.136 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

MTDR

Matador Resources Q2 Adj. EPS $1.53 Beats $1.41 Estimate, Sales $895.312M Miss $900.987M Estimate

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) reported quarterly earnings of $6.14 per share which beat the analyst consensus estimate of $5.96 by 2.97 percent. This is a 14.13 percent increase over earnings of $5.38 per share from the same period last year. The company reported quarterly sales of $12.394 billion which missed the analyst consensus estimate of $12.577 billion by 1.45 percent. This is a 5.21 percent increase over sales of $11.780 billion the same period last year.

Chubb Q2 Adj. EPS $6.14 Beats $5.96 Estimate, Sales $12.394B Miss $12.577B Estimate

CNB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.60 by 5.7 percent. This is a 12.5 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $52.20 million which missed the analyst consensus estimate of $53.17 million by 1.82 percent. This is a 14.17 percent increase over sales of $45.72 million the same period last year.

CCNE

CNB Financial Q2 Adj. EPS $0.63 Beats $0.60 Estimate, Sales $52.20M Miss $53.17M Estimate

Middlefield Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.55 by 38.94 percent. This is a 46.15 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $20.515 million which beat the analyst consensus estimate of $18.300 million by 12.10 percent. This is a 21.80 percent increase over sales of $16.843 million the same period last year.

MBCN

Middlefield Banc Q2 EPS $0.76 Beats $0.55 Estimate, Sales $20.515M Beat $18.300M Estimate

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 2.72% on an annualized basis producing an average annual return of 14.99%. Currently, Halozyme Therapeutics has a market capitalization of $7.09 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 15 years ago, it would be worth $7,914.72 today based on a price of $57.54 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753215315_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

HALO

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) raises FY2025 Adj EPS guidance from $4.54-$4.64 to $4.76-$4.84 vs $4.60 analyst estimate. Raises FY2025 sales outlook from $1.06 billion-$1.07 billion to $1.07 billion-$1.07 billion vs $1.06 billion estimate.

Guidance

MANH

Manhattan Associates Raises FY2025 Adj EPS Guidance from $4.54-$4.64 to $4.76-$4.84 vs $4.60 Est; Raises FY2025 Sales Guidance from $1.06B-$1.07B to $1.07B-$1.07B vs $1.06B Est

Orrstown Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.98 by 6.34 percent. This is a 25.3 percent increase over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $49.512 million which missed the analyst consensus estimate of $49.525 million by 0.03 percent. This is a 89.68 percent increase over sales of $26.103 million the same period last year.

ORRF

Orrstown Finl Servs Q2 Adj. EPS $1.04 Beats $0.98 Estimate, Sales $49.512M Miss $49.525M Estimate

Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) raises FY2025 GAAP EPS guidance from $3.06-$3.16 to $3.23-$3.31 vs $3.09 analyst estimate..

Manhattan Associates Raises FY2025 GAAP EPS Guidance from $3.06-$3.16 to $3.23-$3.31 vs $3.09 Est

<a href="https://www.bloomberg.com/news/articles/2025-07-22/conocophillips-said-to-near-1-3-billion-asset-sale-to-flywheel" title="https://www.bloomberg.com/news/articles/2025-07-22/conocophillips-said-to-near-1-3-billion-asset-sale-to-flywheel">https://www.bloomberg.com/news/articles/2025-07-22/conocophillips-said-to-near-1-3-billion-asset-sale-to-flywheel</a>

'ConocoPhillips Nears $1.3B Asset Sale To Flywheel Energy' -Bloomberg

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is looking for FY2025 GAAP EPS of $1.50-$2.20 vs $1.74 analyst estimate..

USNA

Usana Health Sciences Sees FY2025 GAAP EPS $1.50-$2.20 vs $1.74 Est

First Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCBC#NASDAQ">FCBC</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.65 by 3.08 percent. This is a 15.19 percent decrease over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $40.997 million which beat the analyst consensus estimate of $40.600 million by 0.98 percent. This is a 0.62 percent decrease over sales of $41.254 million the same period last year.

FCBC

First Community Q2 Adj. EPS $0.67 Beats $0.65 Estimate, Sales $40.997M Beat $40.600M Estimate

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) affirms FY2025 Adj EPS guidance from $2.35-$3.00 to $2.35-$3.00 vs $2.61 analyst estimate. Affirms FY2025 sales outlook from $920.000 million-$1.000 billion to $920.000 million-$1.000 billion vs $946.976 million estimate.

Usana Health Sciences Affirms FY2025 Adj EPS Guidance of $2.35-$3.00 vs $2.61 Est; Affirms FY2025 Sales Guidance of $920.000M-$1.000B vs $946.976M Est

Western New England (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNEB#NASDAQ">WNEB</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.14 by 60.84 percent. This is a 35.29 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $21.05 million which beat the analyst consensus estimate of $16.40 million by 28.37 percent. This is a 15.02 percent increase over sales of $18.30 million the same period last year.

WNEB

Western New England Q2 EPS $0.23 Beats $0.14 Estimate, Sales $21.05M Beat $16.40M Estimate

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.54 by 37.04 percent. This is a 37.04 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $235.848 million which beat the analyst consensus estimate of $225.195 million by 4.73 percent. This is a 10.79 percent increase over sales of $212.869 million the same period last year.

Usana Health Sciences Q2 Adj. EPS $0.74 Beats $0.54 Estimate, Sales $235.848M Beat $225.195M Estimate

<a href="https://www.theinformation.com/articles/meta-hires-three-google-ai-researchers-worked-gold-medal-winning-model" title="https://www.theinformation.com/articles/meta-hires-three-google-ai-researchers-worked-gold-medal-winning-model">https://www.theinformation.com/articles/meta-hires-three-google-ai-researchers-worked-gold-medal-winning-model</a>

GOOG

GOOGL

'Meta Hires Three Google AI Researchers Who Worked On Gold Medal-Winning Model' - The Information

Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.13 by 16.24 percent. This is a 11.02 percent increase over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $272.42 million which beat the analyst consensus estimate of $263.61 million by 3.34 percent. This is a 2.68 percent increase over sales of $265.32 million the same period last year.

Manhattan Associates Q2 Adj. EPS $1.31 Beats $1.13 Estimate, Sales $272.42M Beat $263.61M Estimate

Nokia Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares are trading lower Tuesday after the company announced it is cutting its full-year 2025 operating profit outlook due to currency <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46513007/verizon-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">headwinds and tariff impacts. </a>
What To Know: Nokia lowered its comparable operating profit guidance range to between 1.6 billion euros and 2.1 billion euros, down from the previous range of 1.9 billion euros to 2.4 billion euros, issued in January. The company stated that while its core business performed as expected in the first half of the year, the recent weakening of the U.S. dollar and the current tariff environment are now expected to weigh on full-year results.
Nokia cited an estimated 230 million euros negative impact from currency fluctuations, including 140 million euros from operational factors and 90 million euros from non-cash currency revaluations in its venture funds.
The tariff environment is expected to reduce operating profit by an additional 50 million euros to 80 million euros. The company also updated its currency rate assumption, now basing its guidance on a EUR:USD exchange rate of 1.17, compared to the previous 1.04 rate used in January.
In its preliminary second-quarter financial results, Nokia expects net sales of approximately 4.55 billion euros and comparable operating profit of 300 million euros. The second-quarter figure includes 50 million euros negative impact from its venture funds, mostly related to currency movements.
Nokia will release its full second-quarter and half-year results on July 24, 2025, and plans to hold a conference call with investors and analysts that same day to discuss its performance and outlook.
NOK Price Action: Nokia Corporation shares were down 6.11% at $4.46 at publication on Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46549915/el-erian-powell-trump-resign-fed-independence-scott-bessent">El-Erian Says Powell Should Resign—To Save The Fed Itself</a></li>
</ul>
Image Via Shutterstock.

Eurozone

Movers

Nokia Shares Decline After Company Lowers 2025 Operating Profit Guidance

LCNB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCNB#NASDAQ">LCNB</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.38 by 9.33 percent. This is a 41.38 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $22.789 million which beat the analyst consensus estimate of $16.500 million by 38.12 percent. This is a 18.10 percent increase over sales of $19.297 million the same period last year.

LCNB

LCNB Q2 EPS $0.41 Beats $0.38 Estimate, Sales $22.789M Beat $16.500M Estimate

National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.79 by 11.39 percent. This is a 29.41 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $104.475 million which missed the analyst consensus estimate of $110.350 million by 5.32 percent. This is a 7.04 percent increase over sales of $97.603 million the same period last year.

NBHC

National Bank Holdings Q2 EPS $0.88 Beats $0.79 Estimate, Sales $104.475M Miss $110.350M Estimate

Jefferies analyst Blayne Curtis maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $95 to $130.

Price Target

Analyst Ratings

ALAB

Jefferies Maintains Buy on Astera Labs, Raises Price Target to $130

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Caris Life Sciences

CERo Therapeutics Holdings, Inc. - Warrants

CERo Therapeutics Hldgs

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

CERo Therapeutics Hldgs

CERo Therapeutics Hldgs (CEROW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO